

Program

Monday, February 25, 2002

- 9:00 a.m.–9:15 a.m. **Opening Remarks**
Catherine Neary, Ph.D., Chair, CCR FYI
- 9:15 a.m.–10:30 a.m. **Keynote Address—p53: At the Crossroads of Molecular Carcinogenesis and the Molecular Epidemiology of Human Cancer**
Curtis C. Harris, M.D., Chief, Laboratory of Human Carcinogenesis, NCI, NIH
- 10:30 a.m.–11:00 a.m. **Break**
- 11:00 a.m.–12:30 p.m. **Oral Presentations by Attendees—Session I**
- Clinical/Translational Research—*Claudina Aleman, Ph.D.*, Moderator**
Ginger J. Gardner, M.D., Cell and Cancer Biology Branch, CCR, NCI
Peroxisome Proliferator Activated Receptor Gamma (PPAR γ) Ligands Inhibit Ovarian Cancer Cell Growth Title
Jeongwu Lee, Ph.D., Neuro-Oncology Branch, CCR, NCI
In vitro Expansion, Gene Expression Profiling, and Therapeutic Application of Human Adult Bone-Marrow-Derived Neural Stem-Like Cells
Melinda S. Merchant, M.D., Ph.D., Pediatric Oncology Branch, CCR, NCI
Induction of Apoptosis in Ewings Sarcoma Cell Lines Following Treatment with Selective Tyrosine Kinase Antagonist STI571 (Imatinib Mesylate)
Sattva S. Neelapu, M.D., Experimental and Transplantation Immunology Branch, CCR, NCI
Clinical Trial of a Second Generation Lymphoma Vaccine
Hasan Zeytin, M.D., Ph.D., Laboratory of Tumor Immunology and Biology, CCR, NCI
Use of Recombinant Poxvirus Vaccines Expressing Human Carcinoembryonic Antigen (CEA) Combined with GM-CSF to Treat Mice Which Spontaneously Develop CEA-Expressing Colonic Adenomas
- Signal Transduction—*Kathleen Dohoney, Ph.D.*, Moderator**
Bo Chen, Ph.D., Basic Research Laboratory, CCR, NCI
Drm, a BMP Antagonist, Transcriptionally Activates p21^{Cip1} and p27^{Kip1} Expression and Can Inhibit the Tumorigenic Phenotype via a Novel Mechanism
Lindsay Edwards, B.S., Laboratory of Cellular Carcinogenesis and Tumor Promotion, CCR, NCI
mtCLIC, a p53 Regulated Chloride Channel, Translocates to the Nucleus during Apoptosis
Chad Ellis, Ph.D., Cell and Cancer Biology Branch, CCR, NCI
Identification and Characterization of Rig, a Novel Farnesylated Ras-Like GTPase Exhibiting Tumor Suppressor Properties
Shiva Krupa, Ph.D., Basic Research Laboratory, CCR, NCI-Frederick
An Oncogenic c-Kit Mutant Induces Factor-Independent Growth via PI3 Kinase and Jnk-Dependent Pathways
Fang Tian, Ph.D., Laboratory of Cell Regulation and Carcinogenesis, CCR, NCI
Xenograft Models To Address the Roles of Smad2 and Smad3 in Tumorigenesis

Monday, February 25, 2002 (cont'd)

11:00 a.m.–12:30 p.m.

Oral Presentations by Attendees—Session I (cont'd)

Cancer Models and Cancer Prevention—Jackie Lavigne, Ph.D., M.P.H., Moderator

Klaus Felix, Ph.D., Laboratory of Genetics, CCR, NCI

Mutant Frequency in the Transgenic Target/Reporter Gene *lacZ* During Plasmacytomagenesis

Pentao Liu, Ph.D., Mouse Cancer Genetics Program, CCR, NCI-Frederick
Evi9 Can Function as a T-cell Tumor Suppressor Gene, or a B- or Myeloid-Cell Proto-Oncogene, and Is Required for Normal B- and T-Cell Development

Binwu Tang, Ph.D., Laboratory of Cell Regulation and Carcinogenesis, CCR, NCI
The Role of TGF- β s in Tumorigenesis from Xenografts of Human Mammary Gland Epithelial Cell Lines

Anna Maciag, Ph.D., Laboratory of Comparative Carcinogenesis, CCR, NCI-Frederick

→ Expression of Mutant *K-ras* in Lung Epithelial Cells Increases Generation of Reactive Oxygen Species and Oxidative DNA Damage

Wafa Kammouni, Ph.D., Laboratory of Comparative Carcinogenesis, CCR, NCI-Frederick

→ A Proteomic Approach in Study of Growth Arrested Epithelial-Lung Type II Cells

Brown & Goldstein Partnership rules
work w/ young kids

12:30 p.m.–1:30 p.m.

Lunch

1:30 p.m.–2:00 p.m.

Fellows and Young Investigators Association Overview

Catherine Neary, Ph.D., Chair, CCR FYI

Donna L. Vogel, M.D., Ph.D., Director, NCI Fellowship Office

→ Jonathan Wiest, Ph.D., CCR Office of the Director, NCI, NIH

2:00 p.m.–3:00 p.m.

Current Experience with Clinical Translation of Antiangiogenic Therapy

Judah Folkman, M.D., Andrus Professor of Pediatric Surgery and Director of the Surgical Research Laboratory, Children's Hospital, Boston, Massachusetts

3:00 p.m.–3:30 p.m.

Break

3:30 p.m.–5:00 p.m.

Career Panel *No, No, No!*

Christine A. Hrycyna, Ph.D., Walther Assistant Professor of Chemistry, Purdue University

Holly Symonds-Clark, Ph.D., Technology Transfer Specialist, Technology Transfer Branch, NCI, NIH

Jeffrey Silverman, Ph.D., Director, Molecular and Cellular Biology, Av Max, Inc.

Maria Sgambati, M.D., Scientific Writer, Special Communications Expert, NCI, NIH

Diana Linnekin, Ph.D., Investigator, Basic Research Laboratory, NCI, NIH

Donna L. Vogel, M.D., Ph.D., Director, NCI Fellowship Office

English as a second language interest

5:00 p.m.–6:30 p.m.

Poster Session I (with Refreshments)

Clinical/Translational Research (Westminster and Patapsco/Severn Rooms)

Signal Transduction (Westminster and Patapsco/Severn Rooms)

6:30 p.m.–8:00 p.m.

Dinner

7:30 p.m.–8:30 p.m.

The Biologic Paradigm in Oncology

Speaker: Andrew C. von Eschenbach, M.D., Director, NCI, NIH

8:30 p.m.–10:00 p.m.

Social Gathering

Tuesday, February 26, 2002

- 8:30 a.m.–9:30 a.m. **Clinical Research and Cancer Medicine**
Speaker: *Gregory A. Curt, M.D.*, Clinical Director, CCR, NCI, NIH
- 9:30 a.m.–9:45 a.m. **Break**
- 9:45 a.m.–10:45 a.m. **Career Development Workshop I—Parallel Sessions**
→ **Sorting Out Visas at the NIH: Information for Foreign Participants at the NCI**
Deborah S. Fountain, B.S., Human Resources Consultant, NCI, NIH
Interviewing Skills
Alysia Decker, M.Ed., Career Consultant, Johns Hopkins University
- 10:45 a.m.–11:00 a.m. **Break**
- 11:00 a.m.–12:30 p.m. **Oral Presentations by Attendees—Session II**
Pharmacology and Chemistry—*Catherine Neary, Ph.D.*, Moderator
Ayelet Samuni, D.M.D., Ph.D., Radiation Oncology Branch, CCR, NCI
Catecholic Estrogen Mediated Mutagenesis and Carcinogenesis: Chemoprevention Strategies with Antioxidants
Douglas D. Thomas, Ph.D., Radiation Biology Branch, CCR, NCI
Tyrosine Nitration from the Simultaneous Generation of Nitric Oxide and Superoxide Does Not Require Formation of Peroxynitrite: The Role of Heme
Zuben Sauna, Ph.D., Laboratory of Cell Biology, CCR, NCI
The Role of Conserved Residues E556 and E1201 in the Walker B Domain in the Catalytic Cycle of P-glycoprotein
Takahisa Furuta, M.D., Ph.D., Laboratory of Molecular Pharmacology, CCR, NCI
Transcription Coupled-Nucleotide Excision Repair as a Determinant of Cisplatin Activity
Lloyd Lam, Ph.D., Metabolism Branch, CCR, NCI
Gene Expression Profiling of Chemotherapeutic Response in Lymphoma
Molecular Biology and Gene Regulation—*Amit Kumar, Ph.D.*, Moderator
Giovanni Tonon, M.D., Genetics Branch, CCR, NCI
Spectral Karyotyping (SKY) of the Panel of Human Cancer Cell Lines Used in a Drug-Discovery Screen by the National Cancer Institute
Shengyun Fang, M.D., Ph.D., Regulation of Protein Function Laboratory, CCR, NCI
Implication of RING Finger Ubiquitin Ligases in Tumorigenesis and Metastasis
Kevin L. Lorick, Ph.D., Regulation of Protein Function Laboratory, CCR, NCI
BRCA1 Is an Ubiquitin Protein Ligase Whose Activity Is Enhanced by the Non-E3 RING Protein BARD1
Frédéric Catez, Ph.D., Laboratory of Metabolism, CCR, NCI
HMGN Chromosomal Proteins Modulate the Binding of Histone H1 to Chromatin
Xianghong H. Peng, M.D., Laboratory of Cell Biology, CCR, NCI
Role of Conserved Tyrosine401 and Tyrosine1044 in the Nucleotide-Binding Domains of Human P-glycoprotein in Mgatp Binding and Catalytic Activity

Tuesday, February 26, 2002 (cont'd)

- 11:00 a.m.–12:30 p.m. **Oral Presentations by Attendees—Session II (cont'd)**
Immunology and Infectious Diseases—Elizabeth Read-Connole, Ph.D., Moderator
Jennifer L. Troyer, Ph.D., Laboratory of Genomic Diversity, CCR, NCI
FIV-Screening and Sequence Analysis in Wild Feline Species
Yuuei Shu, Ph.D., Laboratory of Experimental and Computational Biology, CCR, NCI-Frederick
Novel Broadly Cross-Reactive HIV-1 Neutralizing Human Monoclonal Antibody Selected for Binding to gp120-CD4-CCR5 Complexes
Terry J. Fry, M.D., Pediatric Oncology Branch, CCR, NCI
Progressive Tumor Growth Does Not Induce Tolerance but Instead Induces Weak Immunity
Stephen C. Bunnell, Ph.D., Laboratory of Cellular and Molecular Biology, CCR, NCI
Visualizing Signaling Assemblies: Dynamic Complex Formation During T Cell Activation
Y. Jeffrey Chiang, Ph.D., Experimental Immunology Branch, CCR, NCI
Cbl-b Deficiency Reveals a CD28 Independent Role for B7 Costimulation
- 12:30 p.m.–2:00 p.m. **Poster Session II (with Lunch)**
Molecular Biology and Gene Regulation (Stadium Ballroom)
- 2:00 p.m.–3:30 p.m. **Poster Session III**
Pharmacology and Chemistry (Westminster Room)
Cancer Models and Cancer Prevention (Patapsco/Severn Rooms)
Immunology and Infectious Diseases (Patapsco/Severn Rooms)
- 3:30 p.m.–4:00 p.m. **Break**
- 4:00 p.m.–5:00 p.m. **Career Development Workshop II—Parallel Sessions**
Jobs in Industry
William T. Schrader, Ph.D., Vice President for Research and Development and Chief Scientific Officer, XenoPharm, Inc.
Setting Up a Lab
Russell Hovey, Ph.D., Assistant Professor, Department of Animal Science, University of Vermont
Matthew F. Mackey, Ph.D., Molecular Immunologist, Aventis Pharmaceuticals
Effective Presentation Skills and Use of Visual Aids
Richard A. Sloane, M.S., Resource Recovery Specialist and Educator, NIEHS, NIH
- 5:00 p.m.–5:30 p.m. **Closing Remarks**
Lee Helmam, M.D., Chief, Pediatric Oncology Branch, CCR, NCI, NIH
- 5:30 p.m. **Adjourn**